Linker design is a critical factor in the success of antibody-drug conjugates (ADCs), influencing stability, targeted delivery, and controlled payload release. CROs provide essential expertise in optimizing linker chemistry to enhance the therapeutic index of ADCs. Through advanced analytical tools, CROs help develop stable linkers that ensure safe circulation while allowing precise payload release at the tumor site. This session will highlight how CROs support the design of innovative linkers by offering services such as stability testing, pharmacokinetic analysis, and tumor selectivity profiling, ultimately improving ADC efficacy and minimizing off-target effects for more effective cancer therapies.